Madrigal Pharmaceuticals (MDGL) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $449.74, -2.19% vs the prior close of $459.81.
- Volume 364.53K shares, 1.4x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
MDGL dips 2.2% to $449.74, a 6-month low. Closed at $449.74, -2.19% vs the prior close of $459.81. Day range $446.61–$462.07, opened at $459.57.
MDGL daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — MDGL dips 2.2% to $449.74, a 6-month low
- Closed at $449.74, -2.19% vs the prior close of $459.81. Day range $446.61–$462.07, opened at $459.57.
- Volume was 364.53K shares, 1.4x its 50-day average of 258.01K.
- Price is -12.6% vs its 50-day average ($514.44) and -11.0% vs its 200-day average ($505.11).
- 52-week range $393.61–$615.00; today's close sits at 25% of that range, 26.9% below the 52-week high.
Oct 15, 2026 — MDGL ends flat (-0.0%) to $459.81
- Closed at $459.81, -0.04% vs the prior close of $460.01. Day range $456.22–$468.72, opened at $464.78.
- Volume was 266.20K shares, 1.0x its 50-day average of 259.68K.
- Price is -10.8% vs its 50-day average ($515.65) and -9.1% vs its 200-day average ($505.78).
- 52-week range $393.61–$615.00; today's close sits at 30% of that range, 25.2% below the 52-week high.
Oct 14, 2026 — MDGL rises 1.7% to $460.01
- Closed at $460.01, +1.75% vs the prior close of $452.12. Day range $452.29–$471.50, opened at $455.52.
- Volume was 326.90K shares, 1.2x its 50-day average of 261.99K.
- Price is -11.0% vs its 50-day average ($516.74) and -9.2% vs its 200-day average ($506.43).
- 52-week range $393.61–$615.00; today's close sits at 30% of that range, 25.2% below the 52-week high.
Oct 13, 2026 — MDGL slides 3.2% to $452.12, a 6-month low, 5 down days in a row
- Closed at $452.12, -3.22% vs the prior close of $467.16. Day range $448.77–$468.65, opened at $467.27.
- Volume was 315.90K shares, 1.2x its 50-day average of 264.95K.
- Price is -12.7% vs its 50-day average ($517.69) and -10.8% vs its 200-day average ($507.12).
- 52-week range $393.61–$615.00; today's close sits at 26% of that range, 26.5% below the 52-week high.
- That makes 5 straight losses.
Oct 12, 2026 — MDGL dips 1.0% to $467.16, a 3-month low, 4 down days in a row
- Closed at $467.16, -0.97% vs the prior close of $471.75. Day range $460.22–$478.85, opened at $471.75.
- Volume was 469.30K shares, 1.7x its 50-day average of 271.46K.
- Price is -9.9% vs its 50-day average ($518.29) and -8.0% vs its 200-day average ($507.88).
- 52-week range $393.61–$615.00; today's close sits at 33% of that range, 24.0% below the 52-week high.
- That makes 4 straight losses.
Oct 9, 2026 — MDGL dips 1.1% to $471.75, a 1-month low, 3 down days in a row
- Closed at $471.75, -1.08% vs the prior close of $476.91. Day range $470.53–$483.64, opened at $477.48.
- Volume was 313.00K shares, 1.1x its 50-day average of 294.96K.
- Price is -9.0% vs its 50-day average ($518.29) and -7.2% vs its 200-day average ($508.55).
- 52-week range $393.61–$615.00; today's close sits at 35% of that range, 23.3% below the 52-week high.
- That makes 3 straight losses.
Oct 8, 2026 — MDGL dips 2.2% to $476.91, a 1-month low
- Closed at $476.91, -2.22% vs the prior close of $487.72. Day range $466.06–$492.33, opened at $486.37.
- Volume was 374.40K shares, 1.3x its 50-day average of 294.61K.
- Price is -8.1% vs its 50-day average ($518.72) and -6.3% vs its 200-day average ($509.21).
- 52-week range $393.61–$615.00; today's close sits at 38% of that range, 22.5% below the 52-week high.
Oct 7, 2026 — MDGL dips 1.8% to $487.72, a 1-month low
- Closed at $487.72, -1.76% vs the prior close of $496.45. Day range $486.77–$502.34, opened at $492.69.
- Volume was 256.20K shares, 0.9x its 50-day average of 293.86K.
- Price is -6.2% vs its 50-day average ($520.12) and -4.3% vs its 200-day average ($509.78).
- 52-week range $393.61–$615.00; today's close sits at 43% of that range, 20.7% below the 52-week high.
Oct 6, 2026 — MDGL rises 0.6% to $496.45
- Closed at $496.45, +0.57% vs the prior close of $493.62. Day range $478.71–$504.06, opened at $497.08.
- Volume was 330.30K shares, 1.1x its 50-day average of 292.62K.
- Price is -4.7% vs its 50-day average ($521.14) and -2.7% vs its 200-day average ($510.06).
- 52-week range $393.61–$615.00; today's close sits at 46% of that range, 19.3% below the 52-week high.
Oct 5, 2026 — MDGL dips 1.2% to $493.62, a 1-month low, 5 down days in a row
- Closed at $493.62, -1.16% vs the prior close of $499.40. Day range $491.25–$505.00, opened at $501.89.
- Volume was 246.50K shares, 0.8x its 50-day average of 290.64K.
- Price is -5.5% vs its 50-day average ($522.23) and -3.3% vs its 200-day average ($510.31).
- 52-week range $393.61–$615.00; today's close sits at 45% of that range, 19.7% below the 52-week high.
- That makes 5 straight losses.
Oct 2, 2026 — MDGL ends flat (-0.1%) to $499.40, a 1-month low, 4 down days in a row
- Closed at $499.40, -0.06% vs the prior close of $499.71. Day range $491.05–$505.00, opened at $505.00.
- Volume was 289.20K shares, 1.0x its 50-day average of 288.07K.
- Price is -4.6% vs its 50-day average ($523.25) and -2.2% vs its 200-day average ($510.61).
- 52-week range $393.61–$615.00; today's close sits at 48% of that range, 18.8% below the 52-week high.
- That makes 4 straight losses.
MDGL latest news & SEC filings
Every SEC filing by or about MDGL in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Sep 28, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 11, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Sibold William John sold 60 shares at $533.09 (≈$31.99K) on Sep 11, 2026
- Sibold William John sold 218 shares at $535.94 (≈$116.83K) on Sep 11, 2026
- Sibold William John sold 160 shares at $537.62 (≈$86.02K) on Sep 11, 2026
- Sibold William John sold 687 shares at $540.59 (≈$371.39K) on Sep 11, 2026
- Sibold William John sold 368 shares at $541.64 (≈$199.32K) on Sep 11, 2026
- Sibold William John sold 1,202 shares at $542.60 (≈$652.21K) on Sep 11, 2026
- …plus 19 more transaction lines in the filing.
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 11, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 9, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 20, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 20, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 12, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Jul 30, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $364.25M (prior year $212.80M) (+71.2% vs Jun 30, 2025)
- Net income: -$57.94M (prior year -$42.28M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$1.99 (prior year -$1.50) (loss widened vs Jun 30, 2025)
Jul 30, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 29, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Things to know before you trade MDGL
- Last results release: Jul 30, 2026 (8-K Item 2.02). Previous ones: May 6, 2026, Feb 19, 2026, Nov 4, 2025. Based on that rhythm, the next report is likely around Oct 29, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 1.14% (largest 3.2%).
- Liquidity: about 285.42K shares (≈$128.37M) trade per day on average.
- 52-week position: $449.74 vs a range of $393.61–$615.00 (25% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: William John Sibold sold 60 shares on Sep 11, 2026.
- Latest filings: 8-K Aug 12, 2026; 10-Q Jul 30, 2026; 8-K Jul 30, 2026.
- Share count: 23.10M shares outstanding (Jul 27, 2026), +3.7% vs a year earlier.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
MDGL market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 459.57 | 462.07 | 446.61 | 449.74 | 364.53K |
| Oct 15, 2026 | 464.78 | 468.72 | 456.22 | 459.81 | 266.20K |
| Oct 14, 2026 | 455.52 | 471.50 | 452.29 | 460.01 | 326.90K |
| Oct 13, 2026 | 467.27 | 468.65 | 448.77 | 452.12 | 315.90K |
| Oct 12, 2026 | 471.75 | 478.85 | 460.22 | 467.16 | 469.30K |
| Oct 9, 2026 | 477.48 | 483.64 | 470.53 | 471.75 | 313.00K |
| Oct 8, 2026 | 486.37 | 492.33 | 466.06 | 476.91 | 374.40K |
| Oct 7, 2026 | 492.69 | 502.34 | 486.77 | 487.72 | 256.20K |
| Oct 6, 2026 | 497.08 | 504.06 | 478.71 | 496.45 | 330.30K |
| Oct 5, 2026 | 501.89 | 505.00 | 491.25 | 493.62 | 246.50K |
| Oct 2, 2026 | 505.00 | 505.00 | 491.05 | 499.40 | 289.20K |
| Oct 1, 2026 | 502.28 | 510.00 | 497.73 | 499.71 | 204.60K |
| Sep 30, 2026 | 513.10 | 515.00 | 501.81 | 503.96 | 262.50K |
| Sep 29, 2026 | 513.73 | 518.67 | 505.32 | 509.44 | 214.40K |
| Sep 28, 2026 | 515.10 | 525.00 | 502.68 | 517.04 | 333.70K |
| Sep 25, 2026 | 513.75 | 523.96 | 511.31 | 516.56 | 153.40K |
| Sep 24, 2026 | 513.65 | 521.77 | 510.57 | 513.21 | 219.30K |
| Sep 23, 2026 | 523.00 | 526.00 | 502.63 | 513.02 | 315.90K |
| Sep 22, 2026 | 525.77 | 528.42 | 516.62 | 518.83 | 266.10K |
| Sep 21, 2026 | 536.04 | 536.04 | 515.98 | 521.96 | 186.10K |
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals (MDGL) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in WEST CONSHOHOCKEN, PA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1157601.
MDGL board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| L.P. 667, | Director | Jun 18, 2026 |
| Bros. Advisors Lp Baker | Director | Jun 18, 2026 |
| Felix Baker | Director | Jun 18, 2026 |
| Julian Baker | Director | Jun 18, 2026 |
| Kenneth Bate | Director | Nov 7, 2025 |
| Bros. Advisors (Gp) Llc Baker | Director | Jun 18, 2026 |
| Brothers Life Sciences Lp Baker | Director | Jun 18, 2026 |
| Daniel J. Brennan | Director | Jun 18, 2026 |
| James M Daly | Director | Jun 18, 2026 |
| Jacqualyn A Fouse | Director | Jun 18, 2026 |
| Paul A Friedman | Director | Jan 13, 2026 |
| Richard S Levy | Director | Jun 18, 2026 |
| John C Reed | Director | Aug 18, 2026 |
| William John Sibold | President and CEO | Sep 11, 2026 |
| Rebecca Taub | Director | Jun 18, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Mardi Dier | EVP and CFO | Mar 6, 2026 |
| Carole Huntsman | Chief Commercial Officer | Mar 6, 2026 |
| Shannon T Kelley | General Counsel | Aug 20, 2026 |
| William John Sibold | President and CEO | Sep 11, 2026 |
| David Soergel | Chief Medical Officer | Jun 1, 2026 |
| Rita Thakkar | Chief Accounting Officer | Jan 20, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 11, 2026 | William John Sibold | Sale | 60 | $533.09 |
| Sep 11, 2026 | William John Sibold | Sale | 218 | $535.94 |
| Sep 11, 2026 | William John Sibold | Sale | 160 | $537.62 |
| Sep 11, 2026 | William John Sibold | Sale | 687 | $540.59 |
| Sep 11, 2026 | William John Sibold | Sale | 368 | $541.64 |
| Sep 11, 2026 | William John Sibold | Sale | 1,202 | $542.60 |
| Sep 11, 2026 | William John Sibold | Sale | 1,539 | $544.02 |
| Sep 11, 2026 | William John Sibold | Sale | 761 | $544.83 |
| Sep 11, 2026 | William John Sibold | Sale | 120 | $546.38 |
| Sep 11, 2026 | William John Sibold | Sale | 106 | $534.06 |
| Sep 11, 2026 | William John Sibold | Sale | 60 | $533.09 |
| Sep 11, 2026 | William John Sibold | Sale | 218 | $535.94 |
| Sep 11, 2026 | William John Sibold | Sale | 160 | $537.62 |
| Sep 11, 2026 | William John Sibold | Sale | 687 | $540.59 |
| Sep 11, 2026 | William John Sibold | Sale | 368 | $541.64 |
MDGL financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $958.40M | $-288.28M | -12.85 | $-189.55M |
| Dec 31, 2024 | $180.13M | $-465.89M | -21.90 | $-455.57M |
| Dec 31, 2023 | $0 | $-373.63M | -19.99 | $-324.23M |
| Dec 31, 2022 | $0 | $-295.35M | -17.23 | $-224.86M |
| Dec 31, 2021 | — | $-241.85M | -14.63 | $-183.92M |
Latest balance sheet: total assets $1.24B, total liabilities $720.92M, cash $292.73M (as of Jun 30, 2026).
MDGL earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Jul 30, 2026 | 8-K Item 2.02 (results) | $493.11 |
| May 6, 2026 | 8-K Item 2.02 (results) | $539.73 |
| Feb 19, 2026 | 8-K Item 2.02 (results) | $436.87 |
| Nov 4, 2025 | 8-K Item 2.02 (results) | $444.64 |
| Aug 5, 2025 | 8-K Item 2.02 (results) | $338.91 |
| May 1, 2025 | 8-K Item 2.02 (results) | $327.70 |
| Feb 26, 2025 | 8-K Item 2.02 (results) | $355.88 |
| Jan 13, 2025 | 8-K Item 2.02 (results) | $303.71 |
| Oct 31, 2024 | 8-K Item 2.02 (results) | $259.34 |
| Aug 7, 2024 | 8-K Item 2.02 (results) | — |
| May 7, 2024 | 8-K Item 2.02 (results) | — |
| Feb 28, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on MDGL
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.